Drug intelligence / Profile preview

ziyuanling

Development stage: Preclinical

Overview

Ziyuanling (滋元灵) is a traditional Chinese medicine (TCM) product referenced in the context of research on chemotherapy-induced thrombocytopenia. It has been studied for its antagonistic effects against gemcitabine-induced bone marrow suppression in mice, suggesting potential use for supporting platelet recovery and mitigating myelosuppression during cancer chemotherapy. The precise herbal composition, mechanism of action, and clinical indications are not fully detailed in available sources, but it is positioned as a TCM intervention aimed at hematological support during cytotoxic therapy[8]. There is no evidence that ziyuanling is an approved pharmaceutical drug or that it has undergone large-scale clinical trials; its use appears to be experimental or investigational within the scope of TCM supportive care.

Other names: 滋元灵

Beyond the preview

Go deeper on ziyuanling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ziyuanling.

Explore the full profile